US 12,447,241 B2
Multi-unit drug delivery devices and methods
Heejin Lee, Bedford, MA (US); Karen Daniel, Newton, MA (US); and Matthew Sansone, Dracut, MA (US)
Assigned to TARIS Biomedical LLC, Lexington, MA (US)
Filed by TARIS Biomedical LLC, Lexington, MA (US)
Filed on Jul. 23, 2020, as Appl. No. 16/936,554.
Application 16/936,554 is a continuation of application No. 14/913,185, granted, now 10,729,823, previously published as PCT/US2014/051672, filed on Aug. 19, 2014.
Claims priority of provisional application 61/867,245, filed on Aug. 19, 2013.
Claims priority of provisional application 61/877,610, filed on Sep. 13, 2013.
Prior Publication US 2020/0353131 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 31/16 (2006.01); A61K 9/00 (2006.01); A61K 31/7068 (2006.01); A61K 47/18 (2017.01); A61L 31/04 (2006.01); A61L 31/08 (2006.01); A61M 31/00 (2006.01)
CPC A61L 31/16 (2013.01) [A61K 9/0004 (2013.01); A61K 9/0034 (2013.01); A61K 31/7068 (2013.01); A61K 47/18 (2013.01); A61L 31/048 (2013.01); A61L 31/08 (2013.01); A61M 31/002 (2013.01); A61K 9/0092 (2013.01)] 7 Claims
 
1. A drug formulation consisting of:
a first plurality of mini-tablets each consisting of:
80.0% by weight gemcitabine HCI;
13.3% by weight urea;
4.2% by weight polyvinylpyrrolidone; and
2.5% by weight polyethylene glycol 8000; and
a second plurality of mini-tablets each consisting of:
90% by weight urea; and
10% by weight one or more excipients.